Holmusk, a Singapore-based healthtech startup, raised USD45m in its Series B funding round. In a statement, Holmusk said it intends to use the investment to continue the rapid expansion of its flagship offering, NeuroBlu Database, which is a leading source of real-world clinical data for the behavioral health industry. Nawal Roy, Holmusk Founder and Chief Executive Officer, said the investment will enable the team to continue its work in curating and enhancing data as it plans to build the world’s largest platform for behavioural health data. The Series B funding round was led by Nasdaq-listed healthcare firm Veradigm Inc., formerly known as Allscripts Healthcare Solutions, Inc. It was participated in by its current investors including Heritas Capital; Health Catalyst Capital; Novartis (dRx Capital); and Northwell Holdings, the venture investment arm of Northwell Health.